Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S127000, C546S124000
Reexamination Certificate
active
10033621
ABSTRACT:
New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
REFERENCES:
patent: 3813404 (1974-05-01), Clarke et al.
patent: 4434151 (1984-02-01), Byrne et al.
patent: 4499099 (1985-02-01), Watts
patent: 4673562 (1987-06-01), Davison et al.
patent: 4746505 (1988-05-01), Jones et al.
patent: 5122361 (1992-06-01), Kung et al.
patent: 5128118 (1992-07-01), Carroll et al.
patent: 5310912 (1994-05-01), Neumeyer et al.
patent: 5334728 (1994-08-01), Kung et al.
patent: 5380848 (1995-01-01), Kuhar et al.
patent: 5413779 (1995-05-01), Kuhar et al.
patent: 5426189 (1995-06-01), Kung et al.
patent: 5439666 (1995-08-01), Neumeyer et al.
patent: 5493026 (1996-02-01), Elmaleh et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5760055 (1998-06-01), Davies
patent: 5980860 (1999-11-01), Kung et al.
patent: 6008227 (1999-12-01), Davies et al.
patent: 6350758 (2002-02-01), Kozikowski et al.
patent: 6353105 (2002-03-01), Meltzer et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6670375 (2003-12-01), Meltzer et al.
patent: 0 135 160 (1985-03-01), None
patent: WO 93/09814 (1993-05-01), None
patent: WO 95/11901 (1995-05-01), None
patent: WO 97/14445 (1997-04-01), None
patent: WO 97/16210 (1997-05-01), None
patent: WO 97/47328 (1997-12-01), None
patent: WO 98/24788 (1998-06-01), None
patent: WO 99/02526 (1999-01-01), None
patent: GB 2349882 (2000-11-01), None
Chen, Tetrahedron Letters 1997, vol. 38, No. 7, pp. 1121-1124, 1997.
Meltzer, Journal of Medicinal Chemistry 2001, vol. 44, No. 17, pp. 2619-2635, 2001.
Zhao, Journal of Medicinal Chemistry 2000, Vo. 43, No. 17, pp. 3283-3294, 2000.
Zhao, Tetrahedron Letters 1999, vol. 40, No. 27, pp. 4961-4964, 1994.
Brandau, et al.,Nucl. Med. Biol. (1994) vol. 21, No. 8, pp. 1073-1081.
Bryson, et al.,Inorg. Chem. (1988), 27, pp. 2154-2161.
Davison, et al.,Inorg. Chem. (1981) vol. 20, No. 6, pp. 1629-1632.
DiZio, et al.,Bioconjugate Chemistry, (1991) vol. 2, No. 5, pp. 353-366.
DiZio, et al.,Journal of Nuclear Medicine(1992) vol. 33, No. 4, pp. 558-569.
Fritzberg, et al.,J. Nucl. Med. (1981) vol. 22, No. 3, pp. 258-263.
Fritzberg, et al.,J. Nucl. Med. (1982)vol. 23, No. 7, pp. 592-598.
Gustavson, et al., NeoRx Corp. Seattle, WA 98119, pp. 5485-5488.
Hansen, et al.,J. Nuc. Med. (1994) vol. 35, No. 7, pp. 1198-1205.
Jones, et al.,J. Nucl. Med, (1982)vol. 23, No. 9, pp. 801-809.
Steigman, et al.,National Academy PressNAS-NS-3204 Prepared for the Committee on Nuclear and Radiochemistry, National Research Council (1992) pp. 117-127.
Archer, et al., University of Essex, Colchester, England, pp. 177-179.
Baldwin, et al., Yale Univ. School of Med., Westhaven, CT, pp. 329-332.
Kelly, et al., Amersham Int., Amersham, Bucks, UK, pp. 259-263.
Kung, et al., Univ. of PA, Philadelphia, PA, pp. 293-298.
Liu et al.,TheDupont Merck Pharm.Co.N. Billerica, MA, pp. 383-393.
Mahmood, et al., Harvard Medical School, Boston, MA, pp. 211-215.
Volkert, Univ. of Missouri Columbia, MO, pp. 17-26.
Davies, et al,J. Med. Chem, (1994) vol. 37, No. 9, pp. 1262-1268.
Bennett, et al.,J. of Pharmacology(1995) vol. 272, No. 3, pp. 1176-1186.
Rao, et al, Eighth International Symposium on Radiopharmaceutical Chemistry, Princeton Univ. (1990) pp. 39-40.
Johannsen, et al.,Eleventh Intern. Symposium Radiopharmaceutical Chem. Abstracts(1995), pp. 319-320.
Agoston, et al.,Amer. Chem. Society, (1997) vol. 40, No. 26, pp. 4329-4339.
Carroll, et al.,J. Med. Chem. (1993) vol. 36, No. 20, pp. 2886-2890.
Casy, et al.,J. Pharm. Pharmacol. (1992)vol. 44, pp. 787-790.
Daum, et al.,J. Med. Chem(1975), vol. 18, No. 5, pp. 496-501.
Holmquist, et al.,J. Med. Chem(1996), vol. 39, No. 21, pp. 4139-4141.
Meegalla, et al.,J. Am. Chem. Soc. (1995) vol. 117, No. 44, pp. 11037-11038.
Meegalla, et al.,J. Am. Chem. Soc. (1996) vol. 7, No. 4, pp. 421-429.
Clarke, et al.,J. Med. Chem. (1973) vol. 16, No. 11, pp. 1260-1267.
Ohmomo, et al.,J. Med. Chem. (1992) vol. 35, No. 1, pp. 157-162.
Carroll, et al.,J. Med. Chem. (1995) vol. 38, No. 2, pp. 379-388.
Kline, et al.,J. Med. Chem. (1997) vol. 40, No. 6, pp. 851-857.
Meltzer, et al.,J. Med. Chem. (1996) vol. 39, No. 2, pp. 371-379.
Meltzer, et al.,J. Med. Chem. (1997) vol. 40, No. 17, pp. 2661-2673.
Meltzer, et al.,J. Med. Chem(1994) vol. 37, No. 13, pp. 2001-2010.
Newman, et al.,J. Med. Chem. (1999) vol. 42, No. 18, pp. 3502-3509.
Newman, et al.,J. Med. Chem. (1995) vol. 38, No. 20, pp. 3933-3940.
Newman, et al.,Current Medicinal Chem. (1998) vol. 5, No. 4, pp. 305-319.
Newman, et al.,J. Med. Chem. (1994) vol. 37, No. 15, pp. 2258-2261.
Riley et al.,J. Med. Chem. (1979) pp. 1167-1171.
Van Eeken, et al.,Arch. Int. Pharmacodyn(Netherlands) (1966) vol. 22, No. 10, vol. 159, No. 1, pp. 240-249.
Cesati, et al.,J. Labelled Cpd. Radiopharm, (1999) vol. 42, Suppl. j, pp. S150-S152.
Fang, et al.,J. Labelled Cpd. Radiopharm. (1999) vol. 42, Suppl. i, pp. S336-S338.
Hoepping, et al., Universitat Marburg, Pachbereich Kemchemie, (1997) pp. 33-36.
Hoepping, et al.,Bioorganic&Medicinal Chem. (1998) vol. 6, pp. 1663-1672.
Hoepping, et al.,Bioorganic&Medicinal Chem. (1996) vol. 6, No. 23, pp. 2871-2874.
Hoepping, et al.,J. Med. Chem. (1998) vol. 41, No. 23, pp. 4429-4432.
Madras, et al.,Synapse(1996) vol. 22, pp. 239-246.
Meegalla, et al.,J. Med. Chem. (1997) vol. 40, No. 1, pp. 9-17.
Meltzer, et al.,J. Med. Chem. (1997) vol. 40, No. 12, pp. 1835-1844.
Meltzer, et al.,J. Med. Chem. (1993) vol. 36, No. 7 pp. 855-862.
Meltzer, et al.,Med. Chem. Research(1998) pp. 12-34.
Meegalla, et al.,Bioconjugate Chem. (1996) vol. 7, No. 4, pp. 421-429.
Fischman, et al.,J. Nuclear Med. (1999) vol. 40, No. 5 Supplement, p. 262P.
Mozley, et al.,J. Nuclear Med. (1995) vol. 36, No. 5, p. 32P.
Myers, et al.,J. Nuclear Med. (1995) vol. 36, No. 5, p. 124P.
Blundell Paul
Madras Bertha K.
Meltzer Peter C.
Aulakh Charanjit S.
Edwards Angell Palmer & & Dodge LLP
Neuner George W.
Organix Inc.
President and Fellows of Harvard College
LandOfFree
Tropane analogs and methods for inhibition of monoamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tropane analogs and methods for inhibition of monoamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tropane analogs and methods for inhibition of monoamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3800583